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Romiplostim reverts the 
thrombocytopenia in den-
gue hemorrhagic fever
To the Editor: First-genera-
tion thrombopoietic agents were 
recombinant forms of human 
thrombopoietin (TPO), but their 
development was discontinued due 
to the onset of neutralizing auto-
antibodies cross-reacting with 
endogenous TPO. Second-gen-
eration thrombopoiesis-stimulat-
ing molecules (romiplostim and 
eltrombopag), have completed 
phase III trials in primary im-
mune thrombocytopenia, whereas 
phase II and III trials are ongoing 
in other conditions characterized 
by thrombocytopenia.1 Dengue 
is the most prevalent arthropod-
borne virus affecting humans to-
day causing a spectrum of disease, 
ranging from a mild febrile illness 
to a life-threatening dengue hem-
orrhagic fever (DHF).2 The main 
hematological findings of dengue 
are leukopenia, thrombocytopenia, 
lymphocytopenia and the presence 
of atypical lymphocytes; in DHF, 
the thrombocytopenia is more pro-
longed, while the other hematolog-
ical abnormalities are not;3 DHF is 
endemic in México.4,5
Multiple myeloma was identi-
fied in November 2007 in a 54-year 
old woman; she was initially treated 
with thalidomide/dexamethasone 
/bortezomib until achieving a very 
good partial response and then 
autografted using high-dose mel-
phalan.6 After the autograft, she 
was given thalidomide, 100 mg/
day. Thirty-six months later she 
developed headache, gastrointesti-
nal symptoms, retro-orbital pain, 
myalgia, joint pain, petechiae, pur-
pura and gum bleeding. The blood 
cell count disclosed thrombocy-
topenia (2×109/L), leukopenia 
(0.7×109/L) and granulocytopenia 
(0.05×109/L); dengue virus anti-
gen and IgM antibodies were pres-
ent; the bone marrow had hypo-
plasia and no evidence of myeloma 
was found. The patient was treated 
with intravenous hydrocortisone 
(300 mg/day) and subcutaneous 
filgrastim (300 ug/day), with the 
neutropenia resolving 4 days later. 
The thrombocytopenia did not re-
solve and was later treated unsuc-
cessfully with oprelvekin and plate-
let transfusions. Fifty-two days 
after the thrombocytopenia en-
sued, subcutaneous romiplostim (4 
ug/Kg/week) was started, and the 
platelet count increased promptly 
(Figure 1). The patient remained 
with >100×109/L platelets, 230 
days after starting romiplostim.
Treatment of dengue fever, 
whether in its uncomplicated form 
or with hemorrhagic manifestations 
remains symptomatic. Steroids have 
proved useful when DHF compli-
cates with septic shock7 and even 
though thrombocytopenia resolves 
spontaneously frequently, may be 
prolonged in certain circumstanc-
es.8 There are reports of anti-D 
immune globulin in DHF cases 
with severe and prolonged throm-
bocytopenia9 but to the best of our 
knowledge, this is the first case of 
DHF in which romiplostim has 
been successfully used. An immune 
mechanism of thrombocytopenia 
due to increased platelet destruc-
tion appears to be operative in pa-
tients with DHF;9 however, in the 
case that we are reporting, the previ-
ous stem cell transplant and the use 
of thalidomide led to a hypoplastic 
marrow which most likely was un-
able to compensate the peripheral 
platelet destruction. 
Romiplostim has been shown to 
be effective in ameliorating throm-
bocytopenia in patients with chronic 
idiopathic thrombocytopenic pur-
pura and other thrombocytopenic 
conditions.10,11 Its usefulness in this 
case may stem from the combined 
origin of the thrombocytopenia, on 
one hand the platelet destruction 
caused by the dengue virus and on 
the other a hyploplastic marrow 
derived not only from the viral in-
fection, but also from the previous 
stem cell allograft and the chronic 
use of thalidomide. 
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 Figure 1. Platelet count (x109/L) by day. Arrows denote doses of romiplostim (4 µg/kg).
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Nasal extranodal periph-
eral NK/T-cell  lymphoma 
treated by the protocol 
NK/T-cell high-dose-meth-
otrexate L-asparaginase 
dexamethasone
To the Editor: Extranodal NK/
T cell lymphoma, a nasal type lym-
phoma, is a distinct entity by the 
WHO classification of lymphomas1 
with a frequency of less than 1% of 
all non-Hodgkin lymphoma (NHL) 
in the West2 and the North Africa3 
and an increased incidence in Asia.4 
Standard treatment is not well estab-
lished and anthracycline containing 
combination chemotherapy (CHOP) 
had less than 30% survival at 5 years 
in localized disease.5 We report a case 
of extranodal NK/T cell lympho-
ma, nasal type, treated initially with 
CHOP as a large cell lymphoma and 
then with high-dose methotrexate, 
L-asparaginase and dexamethasone 
as part of a multicenter phase II clini-
cal trial (GELA-GOELAMS) for 
extranodal NK/T cell lymphoma.
A 34-year-old man, a welder by 
profession for 17 years, was seen in 
September 2008 for a right unilateral 
nasal obstruction associated with re-
current epistaxis (Figures 1,2). There 
were no associated B symptoms and 
performance status was 1. Anterior 
rhinoscopy revealed a right nasal 
cavity ulcerated mass with bleeding 
on touch. There was no other abnor-
mal finding on physical examination 
with no peripheral adenopathy  or 
hepatosplenomegaly. The diagnosis 
of NHL was established after several 
attempts at biopsy due to secondary 
infection and necrosis. The pathology 
was reported as consistent with large 
cell NHL and available immunohis-
tochemistry showed lack of expres-
sion of CD20, CD3, and cytokeratin. 
Patient was staged as Ann Arbor 
stage IEA with no poor prognostic 
factors according to the International 
Prognostic Index. The patient was 
started on CHOP chemotherapy 
but after two cycles, he had a poor 
response with a significant increase 
of the initial lesion and extension to 
the right upper lip. A repeat biopsy 
showed a diagnosis of extranodal 
NK/T-cell lymphoma, nasal type 
with EBV+.
The patient was switched to 
combined treatment with metho-
trexate 3g /m2 on day 1, L-asparagi
nase 6000U/m2 on day 2, 4, 6 and 8 
with dexamethasone 40 mg day 1 to 
day 4 on 21 days cycle for a total of 
three cycles. The patient responded 
nicely and the tumor regressed after 
the first cycle. The patient achieved 
a complete clinical response after a 
second cycle (Figure 3). One month 
after the third cycle, he started ir-
radiation, 30 Gy to the initial site 
of the disease. At the time of last 
follow up at 24 months, he was 
in complete remission (Figure 4). 
In conclucion, extranodal NK/T-
cell lymphoma nasal type is a rare 
entity. Diagnosis may be difficult 
without an appropriate panel of im-
munohistochemistry that may not 
be available in all hospitals, especially 
the detection of cytoplasmic expres-
sion (CD3ε), EBV expression and 
molecular biology techniques. Cases 
with clinical suspicion of extranodal 
NK/T-cell lymphoma should have 
a full panel of immunohistochemis-
try from a tertiary referral center if 
needed. Conventional anthracyclin-
based thereapy (CHOP) has a poor 
outcome. This could be related to 
the overexpression of PGP (multi-
drug resistance) by NK/T tumor 
cells.6 Chemosensitivity to L-aspar-
aginase and high-dose methotrexate 
has encouraging results and should 
be tested in future prospective stud-
ies.7-8 Our patient had 17 years of 
occupational exposure to iron dusts 
and galvanized metals (welding) 
that may had contributed to the de-
velopment of this type of NHL In 
our patient .
